Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections
Background and Aims. To establish the efficacy and safety of ilaprazole, levofloxacin, and amoxicillin as a first-line eradication treatment for Helicobacter pylori. Methods. Patients with gastric ulcer, duodenal ulcer, or gastritis, as detected by esophagogastroduodenoscopy with confirmed H. pylori...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/1654907 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552137541812224 |
|---|---|
| author | Hyo Jun Ahn Dong Pil Kim Myeong Su Chu Hyeon Jeong Yun Seok-Hwan Kim Seung Woo Lee Dong Soo Lee |
| author_facet | Hyo Jun Ahn Dong Pil Kim Myeong Su Chu Hyeon Jeong Yun Seok-Hwan Kim Seung Woo Lee Dong Soo Lee |
| author_sort | Hyo Jun Ahn |
| collection | DOAJ |
| description | Background and Aims. To establish the efficacy and safety of ilaprazole, levofloxacin, and amoxicillin as a first-line eradication treatment for Helicobacter pylori. Methods. Patients with gastric ulcer, duodenal ulcer, or gastritis, as detected by esophagogastroduodenoscopy with confirmed H. pylori infection between September 2014 and November 2015, were enrolled in the study. All participants received ilaprazole (10 mg bid), levofloxacin (500 mg bid), and amoxicillin (1000 mg bid) for 10 days. H. pylori eradication was confirmed by a 13C-urea breath test at 6–8 weeks after the end of treatment. Results. Of 84 patients included in the analysis, the eradication rate was 88.8% in the per protocol group (n=80). Demographic factors such as age, gender, body mass index (BMI), alcohol, smoking, hypertension, diabetes mellitus, and peptic ulcer did not affect the eradication rate. However, multivariate analysis showed that overweight patients and patients with cerebrovascular accident (CVA) had a significantly lower eradication rate than patients with normal BMI and without CVA. Laboratory test results did not change significantly after treatment. A total of six (7.5%) patients developed eight adverse reactions. Conclusions. A 10-day triple therapy containing ilaprazole, levofloxacin, and amoxicillin is a safe alternative first-line eradication treatment for H. pylori. |
| format | Article |
| id | doaj-art-1260098a52f644d78b04e2f2fdd07b7f |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-1260098a52f644d78b04e2f2fdd07b7f2025-02-03T05:59:22ZengWileyGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/16549071654907Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori InfectionsHyo Jun Ahn0Dong Pil Kim1Myeong Su Chu2Hyeon Jeong Yun3Seok-Hwan Kim4Seung Woo Lee5Dong Soo Lee6Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon 34943, Republic of KoreaDivision of Gastroenterology, Department of Internal Medicine, College of Medicine, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon 34943, Republic of KoreaDivision of Gastroenterology, Department of Internal Medicine, College of Medicine, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon 34943, Republic of KoreaDivision of Gastroenterology, Department of Internal Medicine, College of Medicine, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon 34943, Republic of KoreaDivision of Gastroenterology, Department of Internal Medicine, College of Medicine, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon 34943, Republic of KoreaDivision of Gastroenterology, Department of Internal Medicine, College of Medicine, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon 34943, Republic of KoreaDivision of Gastroenterology, Department of Internal Medicine, College of Medicine, Daejeon St. Mary’s Hospital, The Catholic University of Korea, Daejeon 34943, Republic of KoreaBackground and Aims. To establish the efficacy and safety of ilaprazole, levofloxacin, and amoxicillin as a first-line eradication treatment for Helicobacter pylori. Methods. Patients with gastric ulcer, duodenal ulcer, or gastritis, as detected by esophagogastroduodenoscopy with confirmed H. pylori infection between September 2014 and November 2015, were enrolled in the study. All participants received ilaprazole (10 mg bid), levofloxacin (500 mg bid), and amoxicillin (1000 mg bid) for 10 days. H. pylori eradication was confirmed by a 13C-urea breath test at 6–8 weeks after the end of treatment. Results. Of 84 patients included in the analysis, the eradication rate was 88.8% in the per protocol group (n=80). Demographic factors such as age, gender, body mass index (BMI), alcohol, smoking, hypertension, diabetes mellitus, and peptic ulcer did not affect the eradication rate. However, multivariate analysis showed that overweight patients and patients with cerebrovascular accident (CVA) had a significantly lower eradication rate than patients with normal BMI and without CVA. Laboratory test results did not change significantly after treatment. A total of six (7.5%) patients developed eight adverse reactions. Conclusions. A 10-day triple therapy containing ilaprazole, levofloxacin, and amoxicillin is a safe alternative first-line eradication treatment for H. pylori.http://dx.doi.org/10.1155/2017/1654907 |
| spellingShingle | Hyo Jun Ahn Dong Pil Kim Myeong Su Chu Hyeon Jeong Yun Seok-Hwan Kim Seung Woo Lee Dong Soo Lee Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections Gastroenterology Research and Practice |
| title | Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections |
| title_full | Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections |
| title_fullStr | Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections |
| title_full_unstemmed | Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections |
| title_short | Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in Helicobacter pylori Infections |
| title_sort | efficacy and safety of the triple therapy containing ilaprazole levofloxacin and amoxicillin as first line treatment in helicobacter pylori infections |
| url | http://dx.doi.org/10.1155/2017/1654907 |
| work_keys_str_mv | AT hyojunahn efficacyandsafetyofthetripletherapycontainingilaprazolelevofloxacinandamoxicillinasfirstlinetreatmentinhelicobacterpyloriinfections AT dongpilkim efficacyandsafetyofthetripletherapycontainingilaprazolelevofloxacinandamoxicillinasfirstlinetreatmentinhelicobacterpyloriinfections AT myeongsuchu efficacyandsafetyofthetripletherapycontainingilaprazolelevofloxacinandamoxicillinasfirstlinetreatmentinhelicobacterpyloriinfections AT hyeonjeongyun efficacyandsafetyofthetripletherapycontainingilaprazolelevofloxacinandamoxicillinasfirstlinetreatmentinhelicobacterpyloriinfections AT seokhwankim efficacyandsafetyofthetripletherapycontainingilaprazolelevofloxacinandamoxicillinasfirstlinetreatmentinhelicobacterpyloriinfections AT seungwoolee efficacyandsafetyofthetripletherapycontainingilaprazolelevofloxacinandamoxicillinasfirstlinetreatmentinhelicobacterpyloriinfections AT dongsoolee efficacyandsafetyofthetripletherapycontainingilaprazolelevofloxacinandamoxicillinasfirstlinetreatmentinhelicobacterpyloriinfections |